Browse Articles

Discover research articles across all indexed journals

Tislelizumab (TIS) + chemotherapy (chemo) vs placebo (PBO) + chemo as first-line (1L) treatment in gastric/gastroesophageal junction adenocarcinoma (GC/GEJC) patients with/without peritoneal or liver metastases: A post hoc analysis of RATIONALE-305 study.

Journal of Clinical Oncology Miaozhen Qiu, Huiyan Luo, Feng-Hua Wang et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.414

414 Background: Gastric cancer patients with peritoneal or liver metastases had poor prognosis, and the efficacy of immunotherapy in these patients remains unclear. The global phase 3 RATIONALE-305 study (NCT03777657) demonstrated that tislelizumab combined with chemotherapy could bring survival benefits to 1L treatment of GC/GEJC patients. Here, we assessed the efficacy of TIS + chemo vs PBO + chemo in patients with/without peritoneal or liver metastases in RATIONALE-305. Methods: Patients with systemic treatment-naïve GC/GEJC were randomly assigned (1:1) to receive either TIS + chemo or PBO + chemo. Regression analyses were conducted to explore the associations between peritoneal or liver metastases and OS. Relative treatment effect between tislelizumab and placebo was assessed in each subgroup. The Kaplan-Meier method was used to estimate the median OS, and hazard ratios (HRs) for OS were estimated using Cox proportional hazards models. Results: Among the 997 randomized patients (TIS + chemo, n=501; PBO + chemo, n=496), 434 (43.5%) had peritoneal metastases (220 in TIS arm; 214 in PBO arm) and 378 (37.9%) had liver metastases (190 in TIS arm; 188 in PBO arm) at baseline. Regression analyses showed peritoneal and liver metastases were significantly associated with shorter OS. Baseline characteristics were balanced between TIS and chemo arms within each subgroup, including PD-L1 expression levels. As of data cut-off on Feb 28, 2024, OS was longer in the TIS arm compared with the PBO arm in patients with peritoneal metastases (HR= 0.78, 95% CI 0.64-0.96) or without (HR = 0.79, 95% CI 0.65-0.95). OS improvement was also observed in patients with liver metastases (HR = 0.77, 95% CI 0.62-0.96) or without (HR = 0.80, 95% CI 0.67-0.95). Conclusions: This post hoc analysis demonstrated OS improvement with TIS + chemo vs PBO + chemo in GC/GEJC patients with/without peritoneal or liver metastases. To our knowledge, RATIONALE-305 is the first global pivotal study reporting survival benefits with TIS + chemo as 1L treatment for GC/GEJC, irrespective of peritoneal or liver metastases. Clinical trial information: NCT03777657 . With metastases Without metastases TIS arm PBO arm TIS arm PBO arm Peritoneum n=220 n=214 n=281 n=282 Median OS, mo (95% CI) 12.3 (10.6-14.3) 11.8 (10.6-13.0) 17.3 (15.0-20.3) 14.0 (12.6-16.0) HR (95% CI) 0.78 (0.64-0.96) 0.79 (0.65-0.95) Liver n=190 n=188 n=311 n=308 Median OS, mo (95% CI) 13.9 (11.4-15.6) 12.9 (10.9-14.5) 16.0 (13.6-18.0) 12.9 (11.9-14.4) HR (95% CI) 0.77 (0.62-0.96) 0.80 (0.67-0.95)

The relationship between the tumor microenvironment of hepatocellular carcinoma and apparent diffusion coefficient.

Journal of Clinical Oncology Yuji Morine, Yu Saito, Shinichiro Yamada et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.616

616 Background: The tumor microenvironment is critical for the acquisition of tumor malignancy in various cancer types. The objectives of this study were to investigate whether the levels of cancer-associated fibroblasts (CAFs) and tumor-associated macrophages (TAMs) reflect the prognosis of patients with hepatocellular carcinoma (HCC) after hepatectomy (Hx) and to determine whether the apparent diffusion coefficient (ADC) from diffusion-weighted imaging (DWI) reflects CAF and TAM expression. Methods: The study cohort comprised 109 patients who underwent initial curative resection for HCC. Alpha smooth muscle actin (αSMA) was selected as a CAF marker and CD204 as a TAM marker. Protein expression was immunohistochemically evaluated in the intratumoral regions of resected specimens. Clinicopathological factors, including the long-term prognosis after Hx, were investigated between αSMA-negative and -positive tumors and between CD204-negative and -positive tumors. The correlation between CAF/TAM marker expression and the calculated minimum ADC using DWI was also evaluated. Results: αSMA-positive expression was correlated with tumor number, invasive growth pattern, and advanced stage. CD204-positive expression was correlated with the presence of venous invasion. Both αSMA-positive expression and CD204-positive expression were significant prognostic factors in the univariate analysis of overall survival and disease-free survival. αSMA/CD204 double positivity was associated with an extremely poor prognosis after Hx and was a significant independent prognostic factor for overall survival ( p =0.02, hazard ratio: 3.27). Patients with double positivity also showed a significantly higher ADC low rate (83%). Conclusions: Expression of both CAF and TAM markers reflected a poor prognosis after Hx. Furthermore, the preoperative ADC could be a clinical surrogate marker in the tumor microenvironment in patients with HCC.

Perioperative nivolumab results in favourable long-term outcomes in patients with locally advanced resectable non-small-cell lung cancer

Nature Reviews Clinical Oncology Tina Cascone, William N. William Feb 01, 2025 DOI: 10.1038/s41571-024-00976-x

Electrically Generated Exciton Polaritons with Spin On‐Demand (Adv. Mater. 8/2025)

Advanced Materials Yutao Wang, Giorgio Adamo, Son Tung Ha et al. Feb 01, 2025 DOI: 10.1002/adma.202570065

The <i>sp</i> Hybridization of Tin Single Atoms for Dendrite‐Free Sodium Metal Batteries

Advanced Materials Yaguang Li, Yuejiao Li, Jianmin Lu et al. Feb 01, 2025 DOI: 10.1002/adma.202415026

Abstract Restricting the growth of sodium (Na) dendrites at the atomic level is the premise to enable both the stability and safety of sodium metal batteries (SMBs). Here, the universal synthesis of the fourth main group element (Sn, Ge, Pb) as single metal atoms anchored on graphene (Sn, Ge, Pb SAs/G) with sp hybridization for dendrite‐free sodium metal anode is reported. The in situ real‐time observation of Na growth on Sn SAs/G uncoils a kinetically uniform planar deposition at the atomic level for substantially suppressing the dendrite growth. The symmetrical Sn SAs/G‐Na battery exhibits high Coulombic efficiency of 99.8% for 200 cycles, long‐term cyclability with 600 h at 4 mA cm −2 , and ultralow overpotential of 40 mV at 8 mA cm −2 . Further, the full batteries Na 3 V 2 (PO 4 ) 3 ||Sn SAs/G‐Na show unprecedented rate capability of 67 mAh g −1 at 20 C and a capacity retention as high as 91% after 500 cycles. The theoretical calculations of Na deposition on different M SAs/G (M═Sn, Ni, Zn, Fe, Co) reveal that the 5 s 2 5 p 2 electron configuration of Sn SAs/G realizes the planar deposition mechanism of Na clusters along the graphene plane. Therefore, this work provides an atom‐level accurate miniaturization strategy for constructing dendrite‐free SMBs.

A qualitative study of the home-based time burdens faced by persons affected by GI cancer.

Journal of Clinical Oncology Preethiya Sekar, Whitney Victoria Johnson, Manju George et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.822

822 Background: As cancer care is increasingly delivered at home, more tasks and responsibilities fall on patients and informal care partners. This is especially relevant for people with GI cancer who often have specific home-based care needs such as feeding, ostomy care, 5-fluorouracil chemotherapy, and complex medication management. Home-based time costs are undercounted in current measures of time toxicity that only include care received in formal healthcare settings. Methods: We conducted semi-structured interviews with patients with GI cancer and their care partners at a single tertiary cancer center in MN, USA from March-Oct 2023. Interviews explored cancer care tasks at home, associated time burdens, and how they compare to in-facility care. We analyzed interview transcripts using a grounded theory approach to identify themes. Results: We included 33 individuals (11 aged &gt;60y, 21 female, 25 white) including 15 patients (8 colorectal cancer, 8 ECOG 0) and 18 care partners (15 lived with the patient, 7 working at least part-time). We identified 5 themes (Table). Conclusions: This foundational work characterizes time burdens of home-based cancer care for persons affected by GI cancer. In addition to providing the first input on incorporating home-based time burdens into objective measures of time toxicity, we highlight the complexity of assessing time burden which is context and role-dependent. Theme Subtheme Quote Unexpected home-based care is time burdensome Challenge with home as a site of healthcare, difficult transition from hospital to home ‘’What they would do at the clinic behind the scenes she was doing on my kitchen table.” (Patient) Other burdens compound time burdens Logistic/administrative, emotional, symptom “The time spent on administrative things and coordinating [...] are more stressful than going to the clinic.” (Patient) Time burdens evolve over the disease course and differentially impact patients and care partners Cancer care constantly changes, discomfort with some tasks at home, less support provided if more competent, home-based care allows for connection “They’re in a season of remission and [...] we want to live as normal a life as we can. And then there are other seasons where it’s the absolute opposite.” (Care partner) Factors influencing the choice of home-based care Need to manage family duties, supportive care partners matter, value connection with nurses, decreased travel “There is a different cost when you start doing things at home, especially when you have small children because if they’re witnessing it, that’s emotional.” (Patient) Home-based care is generally perceived as less time-burdensome than similar cares provided in-facility Different opinions on whether home-based care should be included in time toxicity measure “If you’re just talking about video visits I wouldn't consider that time toxic. But if I’m going [to the clinic], I’ve pretty much lost the whole day.” (Patient)

KIRROS: A phase II trial in progress of first-line atezolizumab (atezo) with or without bevacizumab (bev) in patients with unresectable hepatocellular carcinoma (HCC) and Child-Pugh B (CPB) cirrhosis.

Journal of Clinical Oncology Amit Singal, Kristen Renee Spencer, Laura Kulik et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.tps647

TPS647 Background: HCC treatment is more complex for the sizable proportion of patients with CPB cirrhosis. These patients have poor survival due to both the cancer and underlying liver dysfunction. As such, they are typically excluded from pivotal clinical trials for first-line systemic therapy for unresectable HCC. The IMbrave150 trial established atezo + bev as a global standard of care for unresectable HCC, demonstrating a statistically significant improvement in overall survival (OS), progression-free survival (PFS) and confirmed objective response rate (ORR) of atezo + bev vs sorafenib (Finn N Engl J Med 2020; Cheng J Hepatol 2022). Real-world studies have consistently suggested benefit of atezo + bev in patients with HCC and CPB cirrhosis (e.g., Tanaka Hepatol Res 2022, D’Alessio Hepatol [Baltimore, Md] 2022). However, prospective clinical trial data are needed to comprehensively characterize safety and efficacy in this population. Single-agent immunotherapy is often used in patients with HCC and CPB cirrhosis given potential safety concerns of combination therapy. Safety data from real-world studies are limited by ascertainment and measurement biases. Therefore, a prospective study is warranted to address the unmet need for safety and efficacy data for first-line atezo ± bev in patients with CPB cirrhosis. Methods: KIRROS (NCT06096779) is a prospective, open-label, multicohort, multicenter phase II study in patients aged ≥18 years who have measurable and confirmed unresectable HCC, and CPB-7 or -8 cirrhosis who have not received prior systemic therapy. Eligible patients will be recruited into 2 cohorts for which endpoints will be non-comparatively assessed: Cohort A (n=60) patients will be treated with atezo 1200 mg intravenous (IV) + bev 15 mg/kg every 3 weeks (Q3W), and Cohort B (n=60) patients, those who do not meet Cohort A inclusion criteria (e.g., main portal vein tumor thrombus and proteinuria), will receive atezo 1200 mg IV Q3W only. Patients will receive treatment until unacceptable toxicity or loss of clinical benefit. The primary objective is to evaluate the safety of the treatment regimens as determined by incidence, nature and severity of adverse events and laboratory abnormalities graded per the National Cancer Institute Common Terminology Criteria for Adverse Events v5.0. Secondary objectives are to estimate efficacy with ORR, duration of response, and PFS per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and HCC modified RECIST, as well as OS. Quality-of-life secondary endpoints include patient-reported tolerability of the treatment regimens assessed by PRO-CTCAE and EORTC IL46, and health-related quality of life per EORTC QLQ-C30 and QLQ-HCC18 scores. As of September 2024, the KIRROS study is recruiting patients at 40 sites in the US and Puerto Rico. Clinical trial information: NCT06096779 .

Association of GPR120 and NGF with perineural invasion in cholangiocarcinoma: Clinical and experimental insights.

Journal of Clinical Oncology Jun He, Lei Qin, Yang Shi et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.622

622 Background: Cholangiocarcinoma (CCA) is a highly malignant biliary tumor characterized by frequent perineural invasion (PNI), which is associated with a poor prognosis; however, the underlying mechanisms remain unclear. G-protein-coupled receptor 120 (GPR120) has been implicated in the development of various tumors, while nerve growth factor (NGF) has a strong correlation with PNI. This study aims to elucidate the role of GPR120 in the production of NGF and to investigate the mechanisms by which PNI is induced in CCA. Methods: We conducted a retrospective review of medical records for 386 patients with cholangiocarcinoma (CCA), including both extrahepatic (ECC) and intrahepatic (ICC) types, who underwent curative resection at the Department of General Surgery, First Affiliated Hospital of Soochow University, between January 2015 and December 2021. NGF and GPR120 expression were assessed in 60 paraffin-embedded archived CCA tissue samples via immunohistochemical staining (IHC), with an additional 60 normal bile duct samples serving as controls. All tissues were sourced from the aforementioned 386 patients, none of whom received preoperative treatment. Tumors were staged according to AJCC classification. Western blot analysis was employed to evaluate NGF and GPR120 expression in CCA cell lines (QBC 939, RBE, HUCCT-1, and HCCC-9810). To assess the invasion and migration capabilities of CCA cell lines, QBC 939 and HCCC-9810 were treated with TUG-891 (a GPR120 agonist) and AH7614 (a GPR120 inhibitor). Results: Both GPR120 and NGF were found to be upregulated in CCA tissues, correlating with aggressive clinicopathological features. IHC staining revealed cytoplasmic localization of GPR120 and NGF, with significantly higher expression in cancerous tissues compared to adjacent noncancerous samples. Among the 386 patients, PNI was observed in 339 (87.8%). PNI correlated with tumor diameter, CA 19-9 levels, TNM stage, preoperative bilirubin levels, tumor differentiation, and preoperative drainage. Notably, GPR120 expression increased in poorly differentiated tumors and advanced clinical stages, indicating a clinical association with CCA progression. In vitro studies demonstrated that GPR120 promoted invasion and migration in the QBC 939 and HCCC-9810 cell lines. Western blot analysis confirmed elevated GPR120 levels in these lines, which also exhibited higher NGF expression. The GPR120 inhibitor AH7614 significantly reduced invasion in QBC 939 and HCCC-9810 cells, while the GPR120 agonist TUG-891 showed no effect on any of the CCA cell lines tested. Conclusions: GPR120 and NGF are implicated in perineural invasion (PNI) in CCA, with a notable correlation between GPR120 and NGF in the context of PNI occurrence.

Getting the right combination to break the epigenetic code

Nature Reviews Clinical Oncology Seda S. Tolu, Aaron D. Viny, Jennifer E. Amengual et al. Feb 01, 2025 DOI: 10.1038/s41571-024-00972-1

Soft Sputtering of Large‐Area 2D MoS<sub>2</sub> Layers Using Isolated Plasma Soft Deposition for Humidity Sensors (Adv. Mater. 8/2025)

Advanced Materials Hye‐Young Youn, Tae‐Yang Choi, Junoh Shim et al. Feb 01, 2025 DOI: 10.1002/adma.202570069

Recent Advances in Next‐Generation Textiles

Advanced Materials Yucheng Tian, Ruida Ding, Sam Sukgoo Yoon et al. Feb 01, 2025 DOI: 10.1002/adma.202417022

Abstract Textiles have played a pivotal role in human development, evolving from basic fibers into sophisticated, multifunctional materials. Advances in material science, nanotechnology, and electronics have propelled next‐generation textiles beyond traditional functionalities, unlocking innovative possibilities for diverse applications. Thermal management textiles incorporate ultralight, ultrathin insulating layers and adaptive cooling technologies, optimizing temperature regulation in dynamic and extreme environments. Moisture management textiles utilize advanced structures for unidirectional transport and breathable membranes, ensuring exceptional comfort in activewear and outdoor gear. Protective textiles exhibit enhanced features, including antimicrobial, antiviral, anti‐toxic gas, heat‐resistant, and radiation‐shielding capabilities, providing high‐performance solutions for healthcare, defense, and hazardous industries. Interactive textiles integrate sensors for monitoring physical, chemical, and electrophysiological parameters, enabling real‐time data collection and responses to various environmental and user‐generated stimuli. Energy textiles leverage triboelectric, piezoelectric, and hygroelectric effects to improve energy harvesting and storage in wearable devices. Luminous display textiles, including electroluminescent and fiber optic systems, enable dynamic visual applications in fashion and communication. These advancements position next‐generation textiles at the forefront of materials science, significantly expanding their potential across a wide range of applications.

Phase Ib study of gevokizumab (GEVO) in combination with standard-of-care (SoC) anticancer therapies in patients (pts) with metastatic colorectal cancer (mCRC), metastatic gastroesophageal cancer (mGEC), and metastatic renal cell cancer (mRCC).

Journal of Clinical Oncology Naureen Starling, Kohei Shitara, Igor Kiss et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.135

135 Background: GEVO, a humanized monoclonal antibody, binds to interleukin-1β (IL-1β) and inhibits its activity. We report results from a phase Ib study of GEVO + SoC anticancer therapies in pts with mCRC/mGEC/mRCC. Methods: This open-label study enrolled pts aged ≥18 years in cohorts A (first line mCRC, [A]), B (second line [2L] mCRC, [B]), C (2L mGEC, [C]) and D (2L/third line mRCC, [D]). The primary objectives were to determine the pharmacodynamically-active dose (PAD) of GEVO monotherapy in A/B, the safety and tolerability, and the recommended dose for expansion (RDE) of GEVO + SoC in A/B/C/D, and the efficacy of GEVO + SoC at RDE in A/B/C measured by the progression-free survival (PFS) rate. The proof of concept (PoC) criteria for PFS rates were ≥42% at 15 months (m) (lower 80% CI limit ≥29%) in A, ≥48% at ~9 m (lower 80% CI limit ≥37%) in B, ≥51% at 6 m (lower 60% CI limit ≥38%) in C. The relationship between baseline levels of high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6) and IL-1β, and on-treatment decrease of circulating tumor DNA (ctDNA) levels with clinical response was explored. Results: As of March 1, 2023, 71 (A), 62 (B), 26 (C) and 7 pts (D) were treated. The PAD was established as 120 mg GEVO intravenous (IV) every 4 weeks (Q4W) and the RDE as 120 mg GEVO IV Q4W + SoC. There were 2 dose-limiting toxicities: grade 4 decreased neutrophil count (1 pt in C) and grade 3 hyponatremia (1 pt in D). The most frequent grade ≥3 treatment-related adverse events (≥15% of all pts) were neutropenia (A/B: 21.1%/22.6%), decreased neutrophil count (A/B/C: 18.3%/17.7%/15.4%) and hyponatremia (D: 28.6%). The PFS rates were 29.0% (80% CI: 20.4, 38.2), 39.4% (80% CI: 29.8, 48.9), 20.0% (60% CI: 13.3, 27.6) in A/B/C, respectively. In B, median PFS and overall survival (OS) were significantly longer in pts with baseline hs-CRP &lt;10 mg/L (low [L]) than ≥10 mg/L (high [H]), IL-6 &lt;9.58 pg/mL (L) than ≥9.58 pg/mL (H), and IL-1β &lt;0.12 pg/mL (L) than ≥0.12 pg/mL (H). In A + B, a median on-treatment decrease of ctDNA fraction by &gt;72% (H) was associated with significantly longer OS. Conclusions: The safety and tolerability of GEVO combinations was acceptable. The primary PFS rates did not meet the PoC criteria. Baseline levels of hs-CRP, IL-6 and IL-1β in pts with 2L mCRC, and on-treatment reduction of ctDNA in pts with 1L + 2L mCRC may have prognostic value. Clinical trial information: NCT03798626 . Variables PFS HR (95% CI) p-value OS HR (95% CI) p-value Ahs-CRP L / HIL-6 L / HIL-1β L / H 1.74 (0.81, 3.73)1.38 (0.70, 2.72)1.50 (0.74, 3.01) 0.1550.3520.259 1.99 (0.66, 5.98)1.73 (0.71, 4.20)0.98 (0.38, 2.52) 0.2210.2250.973 Bhs-CRP L / HIL-6 L / HIL-1β L / H 2.56 (1.27, 5.18)2.92 (1.33, 6.40)2.41 (1.13, 5.13) 0.0090.0070.022 3.04 (1.40, 6.60)3.25 (1.43, 7.36)3.60 (1.54, 8.44) 0.0050.0050.003 A + BctDNA decrease L / H 0.65 (0.39, 1.10) 0.108 0.45 (0.24, 0.83) 0.011

Physical activity and sedentary behavior patterns after early-onset colorectal cancer diagnosis.

Journal of Clinical Oncology Andreana Natalie Holowatyj, Samantha R Keller, Allison Rosen et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.74

74 Background: Sedentary lifestyle and physical inactivity are established risk factors for colorectal cancer diagnosed among adults younger than age 50 years (early-onset CRC). However, patterns of physical activity (PA) and sedentary behavior (SB) in patients after an early-onset CRC diagnosis are less understood. Methods: The Reproductive Health After Cancer Diagnosis and Treatment (REACT) Study is a patient-partnered, cross-sectional study in cooperation with 23 community partners and patient advocates that recruited adults with a first primary cancer (diagnosis age: 18-49 years) over an 8-week period (October to December 2021). Patient-reported sociodemographic, cancer and cancer impact, PA and SB questions were prospectively collected via questionnaire. Frequency, duration and intensity of leisure-time, work-related and transportation-related PA were summed as minutes per week (min/wk). Time spent on SB was calculated by hours spent sitting on a typical day. Diagnosis age- and year-adjusted Spearman correlation coefficients were calculated between PA and SB by cancer treatment status. Results: A total of 131 patients were diagnosed with a first primary early-onset CRC between 2016 and 2021 (median [IQR] age, 40.0 [35-45] years; 82.4% female) in REACT. One hundred thirteen patients (86.3%) were concerned about their physical fitness or getting enough exercise after cancer diagnosis—of whom 62.8% (n=71 of 113) were somewhat or very concerned about their physical fitness/exercise. Among 80 patients with early-onset CRC and complete PA/SB data (86.3% female), 28.8% were not adherent to PA guidelines for aerobic activity (≥150 min/wk) and 56.3% reported long sedentary time (&gt;6 hr/day). The proportion of patients across PA/SB groups also statistically significantly differed by treatment status among those diagnosed between 2019 and 2021 (p=0.049), but not between 2016 and 2018 (p=0.25). While PA was not significantly correlated with SB for early-onset CRC patients who were not actively undergoing treatment (r=-0.16, p =0.32), there was a statistically significant moderate inverse correlation between PA with SB among early-onset CRC patients under active cancer treatment (r=-0.58, p =0.004). Conclusions: One in every 2 early-onset CRC patients reported long sedentary time and one in every 4 early-onset CRC patients in this study did not meet the Physical Activity Guidelines for Americans. With over 80% of patients expressing concern about their physical activity and exercise after an early-onset CRC diagnosis, and differences in PA/SB patterns observed by treatment status, these findings warrant prospective, longitudinal studies of objectively-measured PA and SB among young patients in order to support tailored strategies (e.g., exercise prescriptions) that improve patient health and outcomes across the CRC continuum.

Validation of PDACai v2.0 in predicting relative benefit from frontline FOLFIRINOX (FFX) and gemcitabine/nab-paclitaxel (GA) for patients (pts) with metastatic pancreatic cancer (mPDAC).

Journal of Clinical Oncology Michael J. Pishvaian, Edik Matthew Blais, Lynn M. Matrisian et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.776

776 Background: Novel biomarkers beyond genomic alterations in DDR pathway genes (e.g. BRCA1/2 ) have the potential to optimize frontline and subsequent treatment decisions for mPDAC. This real-world evidence (RWE) study validates PDACai v2.0, a machine learning framework that leverages clinical NGS data to predict progression-free survival (PFS) on FFX vs GA in individual pts with mPDAC. Methods: We analyzed outcomes from 774 pts with mPDAC who underwent genomic profiling via the Know Your Tumor program or were referred to Perthera by treating oncologists. Independent training and validation cohorts receiving either 1st line FFX or GA were split (60:40). PDACai v2.0 integrates an updated set of clinical (age &lt; 63, sex) and lab-agnostic molecular features derived from genomic testing reports (specific KRAS variants, TP53 GOF vs LOF, DDR pathway redefined). Relative benefit scores predicted by FFX or GA models were evenly binned into three PDACai signature categories representing lower, middle, and upper tertiles for each independent cohort. Statistical differences in median PFS were evaluated using ordinal Cox regression. Results: Median PFS followed PDACai predicted trends for each therapy’s training and validation cohorts. The predictive utility of PDACai was confirmed in the independent validation cohorts when comparing PFS on FFX (p = 0.01637; HR = 0.73 [95% CI: 0.56-0.94]) and GA (p = 0.0007506; HR = 0.62 [95% CI: 0.47-0.82]) across tertiles. Conclusions: Using RWE, the PDACai v2.0 signature successfully predicted PFS differences in pts treated with 1st line FFX or GA in mPDAC. Prospective validation efforts and additional data-driven insights into 2nd line PFS on FOLFOX vs 5FU/nal-irinotecan are underway. Summary of actual PFS in months on 1st line therapies in pts assigned to lower, middle, and upper thirds based on relative PDACai v2.0 scores. Independent Cohort (# Pts) Lower TertilemPFS [95% CI] Middle TertilemPFS [95% CI] Upper TertilemPFS [95% CI] 1st line FFX Training (243) 6.5 [5.5-8.1] 9.3 [6.5-13.3] 15.8 [14.1-N/R] 1st line FFX Validation (165) 9.4 [7-13.3] 8.6 [5.6-11.4] 13.2 [9.9-39.6] 1st line GA Training (218) 5.6 [4.7-6.3] 6.9 [5.2-8.2] 11.2 [8.8-13.4] 1st line GA Validation (148) 5.6 [4.2-8.4] 7.5 [6.5-13.1] 8.5 [7.7-11.5]

The changing treatment landscape of EGFR-mutant non-small-cell lung cancer

Nature Reviews Clinical Oncology Fei Zhou, Haoyue Guo, Yang Xia et al. Feb 01, 2025 DOI: 10.1038/s41571-024-00971-2

Trace Adsorptive Removal of PFAS from Water by Optimizing the UiO‐66 MOF Interface (Adv. Mater. 6/2025)

Advanced Materials Nebojša Ilić, Kui Tan, Felix Mayr et al. Feb 01, 2025 DOI: 10.1002/adma.202570048

Passive Isothermal Flexible Sensor Enabled by Smart Thermal‐Regulating Aerogels

Advanced Materials Shenjie Zhong, Bohan Lu, Duan‐Chao Wang et al. Feb 01, 2025 DOI: 10.1002/adma.202415386

Abstract Environmentally induced sensor temperature fluctuations can distort the outputs of a sensor, reducing their stability during long‐term health monitoring. Here, a passive isothermal flexible sensor is proposed by using hierarchical cellulose aerogel (HCA) as the top tribonegative layer, which allows the sensor to adapt dynamic thermal environments through both radiative cooling and heat insulation. The radiative cooling effect can cool down the temperatures of a sensor in summer, while the hollow microfibers in HCA provide ultralow thermal conductivity to reduce internal heat loss in winter. The prepared passive isothermal sensor is capable of maintaining the rated working temperature over an extensive temperature range of 0−100 °C, demonstrating for gripping hot and cold objects. While monitoring human movements under direct sunlight, the temperature of a conventional sensor rose by 12.3 °C, whereas the sensor experienced an increase of only 0.3 °C. Therefore, this work presents a promising strategy for adapting to environments, enabling wearable electronics to function effectively in dynamic thermal conditions.

Final analysis of modified (m)-FOLFOXIRI plus cetuximab versus bevacizumab for <i>RAS</i> wild-type and left-sided metastatic colorectal cancer: The DEEPER trial (JACCRO CC-13).

Journal of Clinical Oncology Akihito Tsuji, Yu Sunakawa, Manabu Shiozawa et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.17

17 Background: The DEEPER trial (NCT02515734), which evaluated m-FOLFOXIRI (irinotecan 150 mg/m², oxaliplatin 85 mg/m², 5-FU 2400 mg/m²) plus cetuximab (cet) vs. bevacizumab (bev) as initial therapy in terms of depth of response (DpR) as the primary endpoint in RAS wild-type metastatic colorectal cancer (mCRC), has demonstrated a significantly better DpR in the cet arm (ASCO 2021). Moreover, favorable progression-free survival (PFS) was reported in the cet arm for patients (pts) with RAS / BRAF wild-type and left-sided tumors (ESMO 2023). Due to the small number of overall survival (OS) events, it was decided to extend the observation period, and the final survival analysis was performed at the cutoff date of August 2024. Methods: Survival analysis was pre-planned in the per-protocol set (PPS), which consisted of pts evaluable for the DpR by an external review board. The clinical outcomes were evaluated according to clinical factors including primary tumor sidedness, liver metastasis status, and BRAF status using a log-rank test. All statistical tests were two-sided, and P values ≤ 0.05 were considered significant. Results: 321 of 359 enrolled pts were defined as PPS (median age 65 years, 64% male, performance status [PS] 0/1: 91%/9%, left/right primary: 84%/16%). In RAS wild-type and left-sided tumors, median PFS and OS were 13.9 months vs. 12.1 months (HR 0.81, 95% CI 0.63-1.05) and 45.3 months vs. 41.9 months (HR 0.85, 95% CI 0.64-1.12) in the cet vs. bev arm, respectively. BRAF status was available in 234 (73%) of the 321 pts in the PPS. An exploratory analysis showed that PFS was significantly better in the cet arm compared to the bev arm (median 14.8 months vs. 11.9 months, HR 0.71, 95% CI 0.52-0.97) in 178 pts with RAS / BRAF wild-type and left-sided tumors. Additionally, OS was 50.2 months vs. 40.2 months (HR 0.74, 95% CI 0.53-1.05). Moreover, according to liver disease status, m-FOLFOXIRI plus cet was associated with longer PFS and OS in pts with RAS / BRAF wild-type and left-sided mCRC with extra-hepatic metastases (median 15.1 months vs. 11.4 months, HR 0.66, 95% CI 0.46-0.95 and 50.2 months vs. 38.6 months, HR 0.60, 95% CI 0.40-0.90), but not liver-limited disease (median 14.5 months vs. 15.5 months, HR 0.79, 95% CI 0.44-1.42 and 52.2 months vs. 49.9 months, HR 1.17, 95% CI 0.61-2.24). Conclusions: The final survival analysis of the DEEPER trial demonstrated favorable PFS and OS with m-FOLFOXIRI plus cet in pts with RAS / BRAF wild-type and left-sided mCRC. The m-FOLFOXIRI plus cet regimen may be a good option for initial therapy, offering longer survival times in pts with extra-hepatic metastases. Clinical trial information: jRCTs061180022 .

Prognostic factors for gastric cancer patients with positive peritoneal cytology who underwent upfront surgery.

Journal of Clinical Oncology Takashi Abe, Masanori Terashima, Keiichi Fujiya et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.400

400 Background: Positive peritoneal cytology (CY1) is classified as Stage IV disease, the standard treatment for which is systemic chemotherapy. However, CY1 is often diagnosed after surgery in patients for whom staging laparoscopy is not indicated. In addition, the treatment strategy for patients with CY1 diagnosed during surgery is controversial. The Japanese guidelines recommend upfront surgery followed by adjuvant chemotherapy for patients diagnosed with CY1 during surgery. To identify patients with CY1 who are most likely to benefit from upfront surgery, we investigated prognostic factors in patients with CY1 who underwent upfront surgery. Methods: A total of 169 gastric cancer patients diagnosed as P0CY1 during or after surgery who underwent R1 resection other than positive resection margins were included. The diagnosis of CY1 was obtained by staging laparoscopy or during laparotomy in 69 patients and after surgery in 87 patients. Fourteen patients were initially diagnosed as CY0 by staging laparoscopy but were rediagnosed as CY1 after surgery. The clinicopathological factors of overall survival (OS) and progression-free survival (PFS) were investigated. Prognostic factors were identified using Cox regression models. Results: The median patient age was 72 years, and there were 108 males. The histological type was undifferentiated type in all of 102 patients. The macroscopic types were 0 in 10) patients 1 in 3, 2 in 27 3 in 84 and 4 in 45). cT grades and cN grades were cT1 in 3, cT2 in 7, cT3 in 12, cT4 in 147, cN0 in 65cN1 in 30), cN2 in 46 and cN3 in 28. The median OS and PFS were 25.1 months and 14.6 months, with 5-year OS rate and PFS rate of 30% and 23%, respectively. A multivariate analysis for OS identified macroscopic type 0-2, Charlson Comorbidity Index&lt;3, and adjuvant chemotherapy as independent prognostic factors. Similarly, macroscopic type 0-2, tumor size &lt;80 mm, and adjuvant chemotherapy were identified as independent prognostic factors for PFS. In a subgroup analysis of patients who received adjuvant chemotherapy, macroscopic type 0-2 was the only independent prognostic factor for PFS. The 5-year PFS rate in patients with macroscopic type 0-2 was 42%. Conclusions: Patients with macroscopic type 0-2 who are suitable for adjuvant chemotherapy may have benefit from upfront surgery, even if peritoneal cytology is positive.

Trends in incidence and survival in anal adenocarcinoma: A SEER study of racial and age disparities.

Journal of Clinical Oncology Supriya Peshin, Shivani Modi, Adit Dharia et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.1

1 Background: Anal adenocarcinoma, a rare but increasingly diagnosed malignancy, has demonstrated rising incidence rates, warranting a deeper analysis of its epidemiology and outcomes across demographic factors like race and age. Methods: A retrospective analysis of data from SEER database (2000-2020) was conducted. Incidence rates per 100,000 individuals and 5-year survival outcomes were compared across racial groups (White, Black, Asian, Hispanic) and age categories (≤50 years, 51-70 years, &gt;70 years). Additionally, trends were analyzed across two decades: 2000-2010 and 2010-2020. This study investigates epidemiological trends of anal adenocarcinoma, focusing on variations in incidence and survival outcomes by race and age, with specific comparisons between the periods 2000-2010 and 2010-2020. Results: Incidence of anal adenocarcinoma increased from 0.7 per 100,000 in 2000 to 1.6 per 100,000 in 2020. From 2000 to 2010, incidence increased rose 0.7 to 1.0 per 100,000, and from 2010 to 2020, it rose from 1.0 to 1.6 per 100,000. Rates were highest among Black individuals, increasing from 1.5 per 100,000 (2000-2010) to 2.3 (2010-2020), followed by White (1.2 to 1.5), Hispanic (0.8 to 1.0), and Asian populations (0.3 to 0.5). Age-related outcomes showed that in 2000-2010, patients aged ≤50 years had a 5-year survival rate of 75% versus 55% in age 51-70 versus 35% for &gt;70 years. In 2010-2020, these rates dropped to 70%, 50%, and 30% in respective age groups. Racial disparities in survival were evident: Black patients had a 5-year survival rate of 40% (2000-2010) and 35% (2010-2020), significantly lower than White patients, who had rates of 65% (2000-2010) and 60% (2010-2020). Conclusions: The incidence of anal adenocarcinoma has steadily increased from 2000 to 2020, particularly among the Black population, while survival rates have declined. Additionally, survival rates are lower in individuals older than 70 years. Highlighting disparities in incidence and outcomes, further research is essential to uncover the underlying causes and develop targeted interventions to mitigate risks and improve patient outcomes. Keywords: anal adenocarcinoma, epidemiology, race, age, survival rates, disparities. This table summarizes the key trends in anal adenocarcinoma incidence and survival by race and age over the two decades from 2000 to 2020. The increases in incidence, particularly among Black individuals, and the worsening survival rates, especially in older and Black populations, are notable findings from the study. Category 2000-2010 2010-2020 Change (2000-2020) Incidence per 100,000 (Overall) 0.7 → 1.0 1.0 → 1.6 +0.9 Incidence by Race - White 1.2 → 1.5 1.5 → 1.5 +0.3 - Black 1.5 → 2.3 2.3 → 2.3 +0.8 - Hispanic 0.8 → 1.0 1.0 → 1.0 +0.2 - Asian 0.3 → 0.5 0.5 → 0.5 +0.2 5-Year Survival by Age - ≤50 years 75% 70% -5% - 51-70 years 55% 50% -5% - &gt;70 years 35% 30% -5% 5-Year Survival by Race - White 65% 60% -5% - Black 40% 35% -5%